|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
D
|
|
INDICATIONS:
|
|
|
|
SIDE EFFECTS:
|
|
abdominal pain |
|
agitation |
|
agranulocytosis |
|
akathisia |
|
anorexia |
|
anxiety |
|
blurred vision |
|
breast enlargement |
|
confusion |
|
constipation |
|
cycloplegia |
|
diarrhea |
|
dizziness |
|
drowsiness |
|
EEG changes |
|
ejaculation dysfunction |
|
eosinophilia |
|
erythema |
|
fever |
|
galactorrhea |
|
gynecomastia |
|
heart failure |
|
hostility |
|
hypertension |
|
ileus |
|
impotence |
|
insomnia |
|
irritability |
|
jaundice |
|
leukopenia |
|
libido decrease |
|
mania |
|
mydriasis |
|
myocardial infarction |
|
nausea/vomiting |
|
ocular hypertension |
|
orgasm dysfunction |
|
orthostatic hypotension |
|
palpitations |
|
photosensitivity |
|
PR prolongation |
|
pruritus |
|
pseudoparkinsonism |
|
purpura |
|
QT prolongation |
|
seizures |
|
serotonin syndrome |
|
SIADH |
|
stroke |
|
suicidal ideation |
|
testicular swelling |
|
thrombocytopenia |
|
tremor |
|
urinary retention |
|
urticaria |
|
vasculitis |
|
ventricular tachycardia |
|
withdrawal |
|
xerostomia |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
hyperthyroidism |
|
hypothyroidism |
|
mania |
|
myocardial infarction |
|
Parkinson's disease |
|
pregnancy |
|
prostatic hypertrophy |
|
radiographic contrast administration |
|
respiratory depression |
|
schizophrenia |
|
seizure disorder |
|
seizures |
|
suicidal ideation |
|
sunlight (UV) exposure |
|
surgery |
|
thrombocytopenia |
|
tobacco smoking |
|
abrupt discontinuation |
|
agranulocytosis |
|
alcoholism |
|
anticholinergic medications |
|
asthma |
|
bipolar disorder |
|
breast-feeding |
|
carbamazepine hypersensitivity |
|
cardiac arrhythmias |
|
cardiac disease |
|
children |
|
closed-angle glaucoma |
|
contact lenses |
|
diabetes mellitus |
|
driving or operating machinery |
|
elderly |
|
gastroesophageal reflux disease (GERD) |
|
GI disease |
|
glaucoma |
|
heart failure |
|
hematological disease |
|
hepatic disease |
|
|
ADULT DOSE:
|
|
Antidepressant-Oral, 25 to 50 mg three or four times a day, the dosage being adjusted as needed and tolerated .
[Urinary incontinence] -Oral, 10 to 50 mg a day , the dosage being adjusted as needed and tolerated, to a maximum of 150 mg a day . |
|
MAXIMUM ADULT DOSE:
|
|
Outpatients: Up to 200 mg a day .
Hospitalized patients: Up to 300 mg a day .
Geriatric patients: Up to 100 mg a day .
|
|
PEDIATRIC DOSE:
|
|
Antidepressant-Children up to 6 years of age: Use is not recommended .
Children 6 to 12 years of age: Oral, 10 to 30 mg a day in two divided doses .
Adolescents: Oral, 25 to 50 mg a day in divided doses, the dosage being adjusted as needed and tolerated, up to 100 mg a day .
Antienuretic-Oral, 25 mg once a day, one hour before bedtime. If a satisfactory response is not obtained within one week, the dosage may be increased to 50 mg nightly in children under 12 years of age and to 75 mg nightly in children 12 or over. |
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
Antidepressant-Oral, initially 25 mg at bedtime, the dosage being adjusted as needed and tolerated, up to 100 mg a day in divided doses . |
|
|
|
|